ProKidney (MEX:PROK) Short-Term Debt : MXN0.00 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is ProKidney Short-Term Debt?

ProKidney's Short-Term Debt for the quarter that ended in Mar. 2024 was MXN0.00 Mil.

ProKidney Short-Term Debt Historical Data

The historical data trend for ProKidney's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProKidney Short-Term Debt Chart

ProKidney Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

ProKidney Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial									-	-	-	-	-

ProKidney Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

ProKidney Short-Term Debt Related Terms

Thank you for viewing the detailed overview of ProKidney's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

ProKidney (MEX:PROK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProKidney Corp (MEX:PROK) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

PROK:USA

Address

2000 Frontis Plaza Boulevard, Suite 250, Winston-Salem, NC, USA, 27103

Website

https://www.prokidney.com

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease.